Back to Search
Start Over
HIV-HBV coinfection among South African patients receiving antiretroviral therapy.
- Source :
-
Antiviral therapy [Antivir Ther] 2010; Vol. 15 (3 Pt B), pp. 499-503. - Publication Year :
- 2010
-
Abstract
- There are approximately 33 million individuals with HIV infection worldwide. The majority of infections are in southern Africa where hepatitis B is also known to be endemic. As access to life-saving antiretroviral therapy (ART) increases, the possibility for hepatitis B treatment resistance increases because most ART regimens contain lamivudine. Patients coinfected with HBV are therefore receiving monotherapy for HBV infection, leading to possible HBV-resistant mutants and the concurrent public health effect thereof. Additional information is needed on the prevalence of HIV-HBV coinfection and treatment response to ART. We present a summary of the information available from South Africa to date.
- Subjects :
- Drug Therapy, Combination
Hepatitis B virus genetics
Humans
Lamivudine therapeutic use
Prevalence
South Africa epidemiology
Anti-HIV Agents therapeutic use
HIV Infections complications
HIV Infections drug therapy
HIV Infections epidemiology
Hepatitis B complications
Hepatitis B epidemiology
Hepatitis B virology
Reverse Transcriptase Inhibitors therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2040-2058
- Volume :
- 15
- Issue :
- 3 Pt B
- Database :
- MEDLINE
- Journal :
- Antiviral therapy
- Publication Type :
- Academic Journal
- Accession number :
- 20516571
- Full Text :
- https://doi.org/10.3851/IMP1494